Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9067554 | 0.77 | TSHR (0.48) | TSHRNFKB1CYP2C19FFAR3 | |
| Hydrochloric Acid SCHEMBL11196712 | 0.75 | TSHR (0.47) | TSHRNFKB1CYP2C19FFAR3 | |
| SCHEMBL20705020 | 0.75 | FFAR3 (0.32) | FFAR3 | |
| SCHEMBL31267911 | 0.75 | FFAR3 (0.32) | FFAR3 | |
| SCHEMBL31267925 | 0.75 | APLNR (0.33) | FFAR3 | |
| Ethylene SCHEMBL11463450 | 0.73 | TSHR (0.45) | TSHRNFKB1CYP2C19FFAR3 | |
| SCHEMBL23397598 | 0.73 | APLNR (0.32) | FFAR3 | |
| SCHEMBL22205962 | 0.73 | APLNR (0.32) | FFAR3 | |
| SCHEMBL22205963 | 0.73 | APLNR (0.32) | FFAR3 | |
| SCHEMBL22205960 | 0.73 | APLNR (0.32) | FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230059865-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| CN-115551847-A | Pyridazine derivatives for modulating nucleic acid splicing | 雷密克斯医疗公司 | 2022-12-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230059865-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | TSHR 4288/4885NFKB1 1053/4885CYP2C19 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.